Heart drug developer Kardigan targets $1.4 billion valuation in US IPO - Reuters
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOd3FqaXptWW5rQTg3MEVQNXJiVGM1aDJ6aGgtNHBqU29nM0Z1UkNJUnF2LXNMSmRqRkMtWEZ6RHNzeHJUMWtVSUMyMGVCZDBFN2UtRVp2c2V3Y2NGSWdxNzA2eDhyVk1lRDBWYzNaMVdscjdjLTRwQTJTNkdPUlZHVVdsNjBxVDIwR3ljSTNLc293REFsNUI3bm5aZWs0ajRPTGFlSm5hWkRWMlFPS3RxaU1WcUpSUUplRk4xV01wd0w2TEJDcXhMd0VYMWdwQkNGdTBB?oc=5" target="_blank">Heart drug developer Kardigan targets $1.4 billion valuation in US IPO</a> <font color="#6f6f6f">Reuters</font>
Clinical-stage biotech Kardigan aims for a valuation of up to $1.4 billion in its U.S. IPO, seeking to raise up to $373.3 million by offering 23.3 million shares priced between $14 and $16 each.
Kardigan has filed for a Nasdaq IPO, offering 23,333,334 shares at a price range of $14 to $16 per share.
Kardigan aims for a valuation of up to $1.4 billion in its U.S. IPO, planning to raise up to $373.3 million by selling 23.3 million shares at a price range of $14 to $16 per share.
Kardigan, Inc has filed for a proposed Nasdaq IPO under the ticker 'KARD', aiming to develop precision medicines for cardiovascular diseases.
Kardigan filed for an initial public offering in the U.S. to fund the development of precision medicines for cardiovascular diseases.
Similar Stories
Related coverage based on topic and tags
Dental firm vVardis reveals revenue surge in US IPO filing - Reuters
Dental firm vVardis reveals revenue surge in US IPO filing Reuters
October 9, 2026 at 07:31 PMAirtel Money slips below IPO offer price in $7 billion London debut - Reuters
Airtel Money slips below IPO offer price in $7 billion London debut Reuters
October 9, 2026 at 12:05 PMAfrica's biggest IPO exposes continent's cross-border investing barriers - Reuters
Africa's biggest IPO exposes continent's cross-border investing barriers Reuters
October 9, 2026 at 05:03 AMNvidia-backed data centre firm scraps IPO as AI valuation concerns deepen
Firmus said it had made the decision due to "recent market volatility and prevailing market conditions".
October 9, 2026 at 04:06 AMNvidia-backed Firmus scraps $5 billion Australian IPO on weak demand - Reuters
Nvidia-backed Firmus scraps $5 billion Australian IPO on weak demand Reuters
October 8, 2026 at 11:47 PMEXCLUSIVE: Refresco plots potential IPO at $10 billion-plus valuation, sources say - Reuters
EXCLUSIVE: Refresco plots potential IPO at $10 billion-plus valuation, sources say Reuters
October 8, 2026 at 09:37 PM